BCI Marketplace
Transcranial Magnetic Stimulation trials

Reduction of Auditory-Verbal Hallucinations in Schizophrenia Through Cortical Neuromodulation

RecruitingNCT06361160Phase: NAStarted 2024-05-21

Summary

Approximately 1% of the general population will be affected by schizophrenia over the course of their lives, with life expectancy being reduced by 20 years on average and quality of life being severely diminished in affected individuals. One third of patients suffering from schizophrenia will evolve towards a resistant form of the disease, amongst which many will suffer from auditory-verbal hallucinations (AVH) that current therapeutic approaches struggle to alleviate. Previous work from our tea

Eligibility

Sex
ALL
Min Age
18 Years
Max Age
None

Inclusion Criteria: * Age \> 18 years old * Schizophrenic Disorder (Diagnostic and statistical manual of mental disorders, DSM-5-TR, American Psychiatric Association, 2013) * AVHs that have resisted to at least two properly conducted antipsychotic therapies at an effective dose for at least 8 weeks

Locations

Groupe Hospitalo-Universitaire Paris Psychiatrie & Neurosciences
Paris, France

Interested in participating? View the full study details on ClinicalTrials.gov:

View on ClinicalTrials.gov →